BeOne Medicines AG

BeOne Medicines AG is a multinational oncology company dedicated to discovering, developing, manufacturing, and commercializing innovative medicines for cancer patients worldwide. Formerly known as BeiGene, Ltd., the company rebranded to BeOne Medicines in November 2024 and redomiciled its legal headquarters to Basel, Switzerland, in May 2025. While maintaining significant operational presences in Cambridge, Massachusetts, U.S., and Beijing, China, its mission is to build a leading global oncology company driven by scientific excellence and speed to expand patient access to transformative therapies.

The company's portfolio primarily focuses on hematologic and solid tumors, featuring key products such as Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor, and Tevimbra (tislelizumab), a PD-1 antibody/inhibitor. These medicines are developed to treat various B-cell malignancies and solid tumors, respectively. BeOne Medicines also engages in global patient safety programs and operates manufacturing facilities for both small and large molecule medicines.

Led by Co-Founder, Chairman, and CEO John V. Oyler, BeOne Medicines continues to advance its pipeline with recent notable developments. In May 2026, the U.S. FDA granted Breakthrough Therapy Designation for sonrotoclax for relapsed or refractory mantle cell lymphoma (MCL), and subsequently approved it. The company also presented promising data at ASCO 2026 for several pipeline candidates, including a CDK4 inhibitor (BGB-43395) for breast cancer, a B7-H4 ADC (BG-C9074) for ovarian cancer, and a bispecific antibody (BGB-B2033) for liver cancer, reinforcing its market positioning as a leader in oncology innovation.